Skip to Content

NanoViricides to Present at the 21st Annual NYBA Meeting in NYC on May 2nd

WEST HAVEN, Conn.--(BUSINESS WIRE)--May 1, 2012 - NanoViricides, Inc. (stock symbol: NNVC) (the "Company") announced today that its President, Dr. Anil R. Diwan, will present an overview of the company at the 21st Annual Meeting of the New York Biotechnology Association (NYBA) in NYC. The Meeting is being held at the Marriott Marquis Hotel in New York City.

NanoViricides, Inc. presentation is scheduled at 11:30am tomorrow, May 2nd, in the “Emerging Companies ShowCase” organized by OneMedPlace in partnership with NYBA ( The presentations in this Showcase event will take place in the Lyceum room of the Hotel. Interested parties – including investors, academics, management, and others – may attend the Emerging Companies Showcase free of charge. In addition, OneMedTV, the television broadcast component of OneMedPlace, will be streaming these investor presentations live at the day of the event.

NanoViricides, Inc. is developing a broad range of anti-viral therapeutics against a number of different viruses. This is enabled by its novel nanoviricides® platform technology. A nanoviricide is designed to look like the cell surface to the virus, complete with the “landing sites” that the virus seeks on the cell surface to bind to the cell and thereafter enter the cell. These “landing sites” are designed into the nanoviricide by chemically incorporating “ligands” to which the virus is expected to bind. The Company strives to develop ligands that closely mimic the native landing sites of the virus. Even as a virus mutates constantly, these landing sites to which the virus binds remain the same. The Company therefore believes that its drugs would be effective against a large range of strains and mutations of a given virus.

The Company has recently declared a clinical drug candidate against influenza in its FluCide™ program, namely, NV-INF-1. The Company has also requested a pre-IND Meeting with the US FDA to discuss the development plan for NV-INF-1.

In addition, the Company has developed drug candidates against HIV, Dengue, and Adenoviral Epidemic Kerato-Conjunctivitis (EKC) that have all shown extremely high efficacies in pre-clinical animal studies. The Company has also developed drug candidates against Herpes that have shown strong efficacies in pre-clinical studies. These additional four commercially important programs are at pre-clinical candidate optimization stage. The Company has several R&D programs against many other viruses including Ebola/Marburg and Rabies viruses.

The Company thus has an extremely broad drug pipeline, enabled by its novel, first-in-class, platform technology. The Company is also developing cGMP manufacturing capabilities for this class of materials.

The Company is planning on two separate indications for NV-INF-1: High strength dosage form for hospitalized patients with severe influenza, and a single course therapy for the out-patients with less severe influenza. A single course treatment for out-patients is a highly sought after goal in influenza therapeutics.

The market size for anti-influenza drugs is currently estimated to be approximately between $4 to $7 billion worldwide. In the USA alone, even in non-pandemic years, up to 20% of the population or about 60 million persons get influenza. The Company believes that if its FluCide™ drug becomes available, the influenza drug market size could expand substantially.

The Company has previously reported on the extremely high efficacies of its optimized FluCide™ drug candidates. The Company is now advancing one of the tested optimized FluCide candidates as the clinical drug candidate after performing substantial further analysis.

About NanoViricides:

NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Contact: NanoViricides, Inc.
Amanda Schuon, 310-550-7200


Posted: May 2012